Yosemite spins up at least one new oncology company using AI by Q1 2027
Resolves: Yosemite publicly announces or files for the formation of a new oncology-focused company that explicitly cites AI as a core component of its drug discovery or development process, with launch or incorporation occurring on or before March 31, 2027.
Yosemite spins up at least one new oncology company using AI by Q1 20…
Market overview
Yosemite has integrated AI into drug discovery and clinical trial design. Given Reed Jobs’ focus on building companies from scratch and the firm’s rapid scaling, it is positioned to launch at least one new oncology venture leveraging AI by the end of Q1 2027.
product prediction market
- Implied probability (Yes)
- 65%
- Closes
- 2027-03-31
About this prediction
Resolution criteria
Yosemite publicly announces or files for the formation of a new oncology-focused company that explicitly cites AI as a core component of its drug discovery or development process, with launch or incorporation occurring on or before March 31, 2027.
Source: user-generated
More product markets
- Will Ocado partnership meet 35% productivity target? — 70% Yes
- Will DCI announce new EV contract worth >$50M? — 55% Yes
- Will the company announce a renewable energy contract by 2026-12-31? — 65% Yes
- Will enGene Therapeutics report positive interim data for DETAIL trial by Q1 2027? — 35% Yes
- Will Phase 2 enrollment reach 50/60 patients by 2026-12-31? — 90% Yes
- Will ServiceTitan announce a major AI partnership or acquisition by end of 2026? — 30% Yes
- Will fintech firms offering real-time fund verification see increased demand? — 75% Yes
- Will private label exceed 33% penetration by EOY? — 60% Yes